Maggon, 2007 - Google Patents
Monoclonal antibody “gold rush”Maggon, 2007
- Document ID
- 1796708264817117877
- Author
- Maggon K
- Publication year
- Publication venue
- Current medicinal chemistry
External Links
Snippet
The market, sales and regulatory approval of new human medicines, during the past few years, indicates increasing number and share of new biologics and emergence of new multibillion dollar molecules. The global sale of monoclonal antibodies in 2006 were $20.6 …
- 108010045030 monoclonal antibodies 0 title abstract description 83
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Maggon | Monoclonal antibody “gold rush” | |
| Dübel et al. | Handbook of therapeutic antibodies | |
| US20220389107A1 (en) | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof | |
| Voge et al. | Monoclonal antibodies in multiple sclerosis: present and future | |
| Baldo | Immune-and non-immune-mediated adverse effects of monoclonal antibody therapy: a survey of 110 approved antibodies | |
| JP6858185B2 (en) | Anti-TfR antibody and its use in the treatment of proliferative and inflammatory diseases | |
| US20200123265A1 (en) | Anti-gitr antibodies and methods of use thereof | |
| CA3006963A1 (en) | Anti-ox40 antibodies and methods of use thereof | |
| CN108137686A (en) | Anti- OX40 antibody and its application method | |
| CN102215868A (en) | Methods for treating progressive multiple sclerosis | |
| CN108136003A (en) | The use in conjunction of anti-PD-1 and anti-M-CSF antibody in treatment of cancer | |
| CN103608040A (en) | Antibodies and other molecules that bind B7-H1 and PD-1 | |
| CN101945893A (en) | Anti-human nkg2d monoclonal antibodies and use thereof | |
| Wang et al. | Biological drug products: development and strategies | |
| US10501775B2 (en) | Antigen binding molecules and methods of use thereof | |
| US11773176B2 (en) | Multispecific antibodies, compositions comprising the same, and vectors and uses thereof | |
| Dübel et al. | Therapeutic Antibodies‐from Past to Future | |
| Schiel et al. | Monoclonal antibody therapeutics: the need for biopharmaceutical reference materials | |
| Mintz et al. | Protein scaffolds | |
| Holgate et al. | Circumventing immunogenicity in the development of therapeutic | |
| TWI821804B (en) | Il-7 binding proteins and their use in medical therapy | |
| JP2023123521A (en) | Methods for treating multiple sclerosis | |
| US11566347B2 (en) | Antibody variants | |
| Shapiro et al. | Regulatory considerations in the development of monoclonal antibodies for diagnosis and therapy | |
| McDonnell | Production of antibodies in hybridoma and non-hybridoma cell lines |